ISSN 1673-3770 CN 37-1437/R
山东大学耳鼻喉眼学报 ›› 2017, Vol. 31 ›› Issue (3): 4-8.doi: 10.6040/j.issn.1673-3770.0.2017.138
许昱,陶泽璋
XU Yu， TAO Zezhang
摘要： 变应性鼻炎的发病率逐年增高,给患者生活质量带来严重影响。药物治疗是变应性鼻炎控制症状主要手段,相关药物各有特点。在进行药物治疗时应遵循规范性和个体化的原则,根据患者主要症状及症状严重程度合理用药,并根据疗效和不良反应情况适时进行药物的升级和降级。
中图分类号:
| [1] Wang XD, Zheng M, Lou HF, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011[J]. Allergy, 2016, 71(8):1170-1180. [2] Juniper EF, Guyatt GH, O'Byrne PM, et al. Aqueous beclomethasonediproprionate nasal spray: regular versus “as required” use in the treatment of seasonal allergic rhinitis[J]. J Allergy Clin Immunol, 1990, 86(3):380-386. [3] Juniper EF, Guyatt GH, Archer B, et al. Aqueous beclomethasonedipropionate in the treatment of ragweed pollen-induced rhinitis: further exploration of “as needed” use[J]. J Allergy Clin Immunol, 1993, 92(1 Pt 1):66-67. [4] Dykewicz MS, Kaiser HB, Nathan RA, et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed(prn)[J]. Ann Allergy Asthma Immunol, 2003, 91(1):44-48. [5] Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials[J]. BMJ, 1998, 317(7173):1624-1629. [6] Yá(~overn)ez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis[J]. Ann Allergy Asthma Immunol, 2002, 89(5):479-484. [7] Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class[J]. Ann Allergy Asthma Immunol, 2010, 104(1):13-29. [8] Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis[J]. Am J Med, 2004, 116(5):338-344. [9] Bielory L, Chun Y, Bielory BP, et al. Impact of mometasonefuroate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis[J]. Allergy, 2011, 66(5):686-693. [10] Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthmaoutcomes in allergic rhinitis: a meta-analysis[J]. Allergy, 2013, 68(5):569-579. [11] Ratner PH, Meltzer EO, Teper A. Mometasonefuroate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2009, 73(5):651-657. [12] Allen DB, Meltzer EO, Jr LR, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year[J]. Allergy Asthma Proc, 2002, 23(6):407-413. [13] Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasonefuroate aqueous nasal spray[J]. Pediatrics, 2000, 105(2):E22. [14] Karaki M, Akiyama K, Mori N. Efficacy of intranasal steroid spray(mometasonefuroate)on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids[J]. Auris Nasus Larynx, 2013, 40(3):277-281. [15] Simons FE. Advances in H1-antihistamines[J]. New Eng J Med, 2004, 351(21):2203-2217. [16] Dizdar EA, Sekerel BE, Keskin O, et al. The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2007, 71(6):843-849. [17] Laekeman G, Simoens S, Buffels J, et al. Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice[J]. Respir Med, 2010, 4(5):615-625. [18] Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis[J]. Otolaryngol Head Neck Surg, 2015, 152(Suppl 1):S1-S43. [19] Horak F, Zieglmayer UP, Zieglmayer R, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy[J]. Curr Med Res Opin, 2006, 22(1):151-157. [20] Kaliner MA, Berger WE, Ratner PH, et al. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis[J]. Allergy Asthma Immunol, 2011, 106(Suppl 2):S6-S11. [21] Laforce CF, Corren J, Wheeler WJ, et al. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine[J]. Ann Allergy Asthma Immunol, 2004, 93(2):154-159. [22] Kaliner MA. Azelastine and olopatadine in the treatment of allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2009, 103(5):373-380. [23] Carr WW, Ratner P, Munzel U, et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis[J]. Allergy Asthma Proc, 2012, 33(6):450-458. [24] Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review[J]. Drugs, 2007, 67(6):887-901. [25] Van AJ, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period[J]. Allergy, 2003, 58(58):1268-1276. [26] Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions[J]. Pediatr Pulmonol, 2009, 44(6):568-579. [27] Mösges R, Klimek L. Todays allergic rhinitis patients are different: new factors that may play a role[J]. Allergy, 2007, 62(9):969-975. [28] Anolik R. Clinical benefits of combination treatment with mometasonefuroate nasal spray and loratadinevsmonotherapy with mometasonefuroate in the treatment of seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2008, 100(3):264-271. [29] Can D, Tanaç R, Demir E, et al. Is the usage of intranasal glucocorticosteroids alone in allergic rhinitis sufficient?[J]. Allergy Asthma Proc, 2006, 27(3):248-253. [30] Nasser M, Fedorowicz Z, Aljufairi H, et al. Antihistamines used in addition to topical nasal steroids for intermittent and persistent allergic rhinitis in children[J]. Cochrane Database Syst Rev, 2010, 7(7):CD006989. [31] Hilberg O. Effect of terfenadine and budesonide on nasal symptoms, olfaction, and nasal airway patency following allergen challenge[J]. Allergy, 1995, 50(8):683-688. [32] Ratner PH, Hampel F, Bavel JV, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2008, 100(1):74-81. [33] Hampel FC, Ratner PH, Van BJ, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device[J]. Ann Allergy Asthma Immunol, 2010, 105(2):168-173. [34] Laforce CF, Carr W, Tilles SA, et al. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis[J]. Allergy Asthma Proc, 2010, 31(2):132-140. [35] Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis[J]. J Allergy Clin Immunol, 2012, 129(129):1282-1289.e10. [36] Rael EL, Ramey J, Lockey RF. Oxymetazoline hydrochloride combined with mometasone nasal spray for persistent nasal congestion(pilot study)[J]. World Allergy Organ J, 2011, 4(3):65-67. [37] Meltzer EO, Bernstein DI, Prenner BM, et al. Mometasonefuroate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis[J]. Am J Rhinol Allergy, 2013, 27(2):102-108. [38] Cingi C, Gunhan K, Gage-White L, et al. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis[J]. Laryngoscope, 2010, 120(9):1718-1723. [39] Rodrigo GJ, Ya(~overn)ez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials[J]. Ann Allergy Asthma Immunol, 2006, 96(6):779-786. [40] Lu S, Malice MP, Dass SB, et al. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis.[J]. J Asthma, 2009, 46(9):878-883. [41] Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall[J]. Ann Allergy Asthma Immunol, 2002, 88(6):592-600. [42] Esteitie R, Detineo M, Naclerio RM, et al. Effect of the addition of montelukast to fluticasone propionate for the treatment of perennial allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2010, 105(2):155-161. [43] Goh BS, Ismail MI, Husain S. Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: a randomised, double-blind, placebo-controlled study[J]. J Laryngol Otol, 2014, 128(3):242-248. [44] 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎诊断和治疗指南(2015年,天津)[J]. 中华耳鼻咽喉头颈外科杂志, 2016, 51(1):6-24. Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of allergic rhinitis[J]. Chin J Otorhinolaryngol Head Neck Surg, 2016, 51(1):6-24. [45] Meltzer EO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions.[J]. Allergy Asthma Proceed, 2013, 34(4):301-311. [46] Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma(ARIA)2008 update(in collaboration with the World Health Organization, GA(2)LEN and AllerGen)[J]. Allergy, 2008, 63(Suppl 86):8-160. |
| [1] | 吕倩,唐源,顾子君,施赛磊,刘萍,万文锦. 变应性鼻炎患者疾病获益感现状及影响因素分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 21-28. |
| [2] | 顾敏,陆美萍. 纳米药物输送系统在变应性鼻炎过敏原免疫治疗中的应用进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 106-111. |
| [3] | 秦娜娜,李玉芬,孙雨浩,魏健,李钦. 基于TGF-β1/Smad信号通路探讨白细胞介素13受体α2对变应性鼻炎大鼠鼻黏膜组织重塑的影响[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 71-77. |
| [4] | 熊琴, 张砚, 乌日娜, 李锋, 唐力行. 鼻用糖皮质激素在儿童中的应用[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 160-167. |
| [5] | 许雪萌,樊磊,喻望博,蒋芝月,潘晨,黄泳芹. 奥马珠单抗联合特异性免疫治疗变应性鼻炎疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 26-33. |
| [6] | 刘怡君,谷悦,官大宇,杨玉成,沈暘. 翼管神经切断术在难治性变应性鼻炎中远期临床疗效和安全性[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 42-48. |
| [7] | 张婷,王美兰,高映勤. 白细胞介素35在变应性鼻炎中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 139-147. |
| [8] | 张竹萍,彭孜灿,肖振龙,李程,喻迪,王兴龙,陈伟,郭蓓. 新型鼻分泌物嗜酸粒细胞阳离子蛋白-髓过氧化物酶试纸在变应性鼻炎中的应用价值[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 129-134. |
| [9] | 刘畅,杨景朴,高雨,王文佳. 长春地区儿童变应性鼻炎变应原检测结果分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 51-58. |
| [10] | 周荷青,申琪. 中医药治疗变应性鼻炎疗效的生物标志物研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 168-176. |
| [11] | 王曼娴,郑泉,杨亮. 细菌裂解物治疗变应性鼻炎的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 141-145. |
| [12] | 刘畅,方宏艳,刘敩,富东娜,王贺,王晶,杨景朴. 长春地区秋季变应性鼻炎蒿属花粉致敏特征分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 13-19. |
| [13] | 朱朗,刘志奇. 移动医疗提供的真实世界数据在变应性鼻炎治疗方案中的参考[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 135-139. |
| [14] | 张静祎,董湘依,牟亚魁,宋西成. 细胞焦亡在耳鼻咽喉科疾病中的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 140-148. |
| [15] | 张丽净,冯晓星,刘南仙,赵辉明,陈月华. 石墨烯养护鼻罩结合尘螨的皮下特异性免疫治疗在尘螨变应性鼻炎患者中的应用分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 26-32. |
|
||